Efficacy of dapiprazole.
A study was performed to evaluate the clinical usefulness of dapiprazole in a private clinical setting. This study was unmasked, but used one eye of each subject as a control. Thirty consecutive subjects were given dapiprazole as directed by the manufacturer. The administration of dapiprazole followed bilateral dilation for routine fundus examination. Subjects were dilated using one drop each of proparacaine 0.5%, tropicamide 1.0%, and phenylephrine 2.5%. Pupil diameter, amplitude of accommodation, and conjunctival injection were evaluated. Each of these three variables was measured (1) before instillation of the diagnostic agents, (2) before the instillation of diapiprazole, and (3) at 30, 60, 120, and 180 min after the final instillation of dapiprazole. The average pupillary recovery time for dapiprazole-treated eyes was similar to previously published data. Accommodation also showed significant recovery, with comfortable reading ability returning after approximately 30 min. The design of our study did not permit us to determine what portion of accommodation recovery was attributable to alpha ciliary muscle effect and what portion resulted from the increased depth of field that was due to the pupillary constriction. All of our subjects exhibited conjunctival hyperemia after the administration of dapiprazole. This side effect persisted through the entire 180-min observation period that followed dapiprazole administration.
Johnson
M E
ME
Molinari
J F
JF
D000065:Accommodation, Ocular / Q000187:drug effects; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D002924:Ciliary Body / Q000187:drug effects; D003228:Conjunctiva / Q000098:blood supply / Q000187:drug effects; D006801:Humans; D006940:Hyperemia / Q000139:chemically induced; D009883:Ophthalmic Solutions; D010656:Phenylephrine / Q000008:administration & dosage / Q000037:antagonists & inhibitors; D010879:Piperazines; D011680:Pupil / Q000187:drug effects*; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*; D014331:Tropicamide / Q000008:administration & dosage / Q000037:antagonists & inhibitors
D000317:Adrenergic alpha-Antagonists; D009883:Ophthalmic Solutions; D010879:Piperazines; D014230:Triazoles; D010656:Phenylephrine; C035289:dapiprazole; D014331:Tropicamide